Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

By sjmartinez • March 8, 2023

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. J Clin Oncol. 2023 Mar 10;41(8):1501-1510. doi: 10.1200/JCO.22.02510. PMID: 36881998.

Tags: Hematology/Oncology, Publications

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis

Zaorsky NG, Sun Y, Nabid A, Zapatero A, Bolla M, Joseph D, Maingon P, Guerrero A, Gonzalez AA, San-Segundo CG, Cabeza Rodríguez MÁ, Sole JM,[...]

Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer

Barnes DR, Tyrer JP, Dennis J, Leslie G, Bolla MK, Lush M, Aeilts AM, Aittomäki K, Andrieu N, Andrulis IL, Anton-Culver H, Arason A, Arun[...]

Oncoplastic Breast Surgery: Optimizing Resection Margins in Addition to Aesthetic Outcomes

Yesantharao PS, Shaheen MS, Hui G, Gombar S, Momeni A. Oncoplastic Breast Surgery: Optimizing Resection Margins in Addition to Aesthetic Outcomes. Aesthetic Plast Surg. 2025[...]